Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Status:
Completed
Trial end date:
2018-06-21
Target enrollment:
Participant gender:
Summary
This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and
Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day
for 6 months.
Phase:
Phase 1
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)